Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.08
-2.7%
$1.33
$0.88
$1.71
$127.92M0.72374,893 shs344,231 shs
Cyanotech Co. stock logo
CYAN
Cyanotech
$0.44
$0.40
$0.21
$0.57
$3.25M0.15672 shs20 shs
JAN stock logo
JAN
JAN
$25.03
-0.4%
$25.50
$22.76
$28.52
$6.59B2.161.15 million shs1.63 million shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.59
-1.9%
$1.62
$1.44
$3.35
$65.70M0.0244,263 shs22,757 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.00%-9.02%-15.91%+13.33%-21.28%
Cyanotech Co. stock logo
CYAN
Cyanotech
0.00%+18.92%+13.08%+2.33%+10.00%
JAN stock logo
JAN
JAN
0.00%-6.44%-9.59%+240.81%+240.81%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%-5.54%-0.61%-5.26%-14.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.08
-2.7%
$1.33
$0.88
$1.71
$127.92M0.72374,893 shs344,231 shs
Cyanotech Co. stock logo
CYAN
Cyanotech
$0.44
$0.40
$0.21
$0.57
$3.25M0.15672 shs20 shs
JAN stock logo
JAN
JAN
$25.03
-0.4%
$25.50
$22.76
$28.52
$6.59B2.161.15 million shs1.63 million shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.59
-1.9%
$1.62
$1.44
$3.35
$65.70M0.0244,263 shs22,757 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.00%-9.02%-15.91%+13.33%-21.28%
Cyanotech Co. stock logo
CYAN
Cyanotech
0.00%+18.92%+13.08%+2.33%+10.00%
JAN stock logo
JAN
JAN
0.00%-6.44%-9.59%+240.81%+240.81%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%-5.54%-0.61%-5.26%-14.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.33
Hold$8.50683.41% Upside
Cyanotech Co. stock logo
CYAN
Cyanotech
0.00
N/AN/AN/A
JAN stock logo
JAN
JAN
2.83
Moderate Buy$28.4513.70% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.40
Hold$6.33295.83% Upside

Current Analyst Ratings Breakdown

Latest JAN, CYAN, CRDL, and OKYO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/1/2026
JAN stock logo
JAN
JAN
Boost Price TargetOverweight$27.00 ➝ $31.00
5/27/2026
JAN stock logo
JAN
JAN
Boost Price TargetOutperform$28.00 ➝ $30.00
5/27/2026
JAN stock logo
JAN
JAN
Boost Price TargetSector Outperform$28.00 ➝ $30.00
5/13/2026
JAN stock logo
JAN
JAN
Boost Price TargetOverweight$26.00 ➝ $30.00
5/8/2026
JAN stock logo
JAN
JAN
Boost Price TargetOutperform$27.00 ➝ $30.00
4/21/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
Reiterated RatingSell (D-)
4/15/2026
JAN stock logo
JAN
JAN
UpgradeHold
4/14/2026
JAN stock logo
JAN
JAN
Initiated CoverageNeutral$27.00
4/14/2026
JAN stock logo
JAN
JAN
Initiated CoverageOutperform$27.00
4/14/2026
JAN stock logo
JAN
JAN
Initiated CoverageOverweight$27.00
4/14/2026
JAN stock logo
JAN
JAN
Initiated CoverageOutperform$27.00
(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.11 per shareN/A
Cyanotech Co. stock logo
CYAN
Cyanotech
$24.22M0.13N/AN/A$1.23 per share0.36
JAN stock logo
JAN
JAN
$822.58M8.01N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.16) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)
Cyanotech Co. stock logo
CYAN
Cyanotech
-$3.20M-$0.25N/AN/AN/A-7.03%-20.62%-7.52%N/A
JAN stock logo
JAN
JAN
N/AN/AN/AN/AN/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$4.71MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)

Latest JAN, CYAN, CRDL, and OKYO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$0.07-$0.07N/A-$0.07N/AN/A
5/5/2026Q1 2026
JAN stock logo
JAN
JAN
$0.23$0.23N/A$0.23$157.96 million$200.35 million
3/30/2026Q4 2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$0.09-$0.05+$0.04-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
Cyanotech Co. stock logo
CYAN
Cyanotech
N/AN/AN/AN/AN/A
JAN stock logo
JAN
JAN
$0.642.56%N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A

Latest JAN, CYAN, CRDL, and OKYO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2026
JAN stock logo
JAN
JAN
quarterly$0.15992.26%6/12/20266/12/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/A
4.39
4.39
Cyanotech Co. stock logo
CYAN
Cyanotech
0.12
1.00
0.30
JAN stock logo
JAN
JAN
N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
0.58
N/A

Institutional Ownership

CompanyInstitutional Ownership
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
Cyanotech Co. stock logo
CYAN
Cyanotech
24.40%
JAN stock logo
JAN
JAN
6.27%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
5.25%
Cyanotech Co. stock logo
CYAN
Cyanotech
34.40%
JAN stock logo
JAN
JAN
3.00%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
20115.25 million109.20 millionNot Optionable
Cyanotech Co. stock logo
CYAN
Cyanotech
957.39 million4.85 millionNot Optionable
JAN stock logo
JAN
JAN
N/A263.14 millionN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
740.56 million24.15 millionNot Optionable

Recent News About These Companies

OKYO Pharma Announces Director Acquires Shares
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.08 -0.03 (-2.70%)
Closing price 04:00 PM Eastern
Extended Trading
$1.10 +0.01 (+1.39%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cyanotech stock logo

Cyanotech OTCMKTS:CYAN

$0.44 0.00 (0.00%)
As of 06/5/2026

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

JAN stock logo

JAN NYSE:JAN

$25.02 -0.10 (-0.38%)
Closing price 03:59 PM Eastern
Extended Trading
$25.04 +0.02 (+0.08%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Upon completion of this offering, we will be the only U.S. publicly traded REIT focused exclusively on the senior housing sector and the only U.S. publicly traded REIT whose entire portfolio is owned and operated under RIDEA structures. We have an initial portfolio consisting of 34 senior housing communities, comprised of 10,422 units as of December 31, 2025. Our communities are located primarily in major retirement markets across 10 states, with units in Florida and Texas representing 69% of the total units as of December 31, 2025. All of our communities are owned and operated under RIDEA structures. Services provided by our operators under a RIDEA structure are primarily paid for directly by the residents, rather than governmental reimbursement programs, which provides us with greater visibility into operating cash flow from our communities. We will be externally managed by Healthpeak Investment Management, LLC, an indirect subsidiary of Healthpeak, which will be our largest stockholder following the completion of this offering and the formation transactions. Healthpeak is an S&P 500 REIT that invests in and manages real estate focused on healthcare discovery and delivery in the United States. Although our Manager was recently formed, Healthpeak has been a public company and an active investor in healthcare real estate for over 40 years. Healthpeak has an extensive network for sourcing and managing senior housing investments that it has established over its long operating history, and we will benefit from this network through our Manager. Our initial portfolio reflects our commitment to delivering sustainable growth through differentiated senior housing solutions and strategic collaborations with high quality operators. We intend to focus exclusively on the senior housing sector because we believe that favorable demographic trends will enable us to create long-term value for our stockholders. We intend to grow our initial portfolio by drawing on our Manager’s origination and sourcing capabilities and established relationships to execute on attractive investment opportunities in the senior housing sector. Of the 34 senior housing communities in our initial portfolio, we describe 15 of these communities, comprising an aggregate of 7,067 units as of December 31, 2025, as “life plan communities.” Life plan communities are a form of senior housing that offer a full continuum of care, including independent living, assisted living, memory care, and skilled nursing, in large-scale communities. Life plan communities differ from other housing and care options for seniors because they typically operate under an entrance fee model, which requires a one-time entrance fee in addition to monthly resident fees, and offer integrated housing, activities, services, and healthcare benefits on a single campus. Life plan communities are designed for individuals and couples seeking an active lifestyle where they can avoid moving a second or third time as they age, and most entrance fee contracts include some level of discounted rates on future healthcare. Compared to traditional rental senior housing, life plan communities offer resident-driven decision making, lifestyle choice, peace of mind from continuum of care, and larger units, with most of our independent living units averaging approximately 1,100 square feet. Residents typically enter our life plan communities in good health in their late 70s or early 80s and stay for eight to ten years — substantially longer than in traditional rental senior housing — supporting stable occupancy and predictable cash flows. The large size of our life plan community campuses, spanning 48 acres of land on average and consisting of approximately 471 units on average as of December 31, 2025, allows us to offer more substantial indoor and outdoor amenities to provide a highly active social life for seniors and create a differentiated senior housing product with high barriers to entry. Due to sizeable land needs, high development costs, financing challenges and pre-leasing requirements, new supply of life plan communities is very low, thereby enabling favorable supply and demand fundamentals for incumbents. We believe life plan communities exhibit consistently resilient occupancy, positioning them as a business with embedded operating leverage and growth visibility, which in turn can provide strong risk-adjusted returns. The other 19 senior housing communities in our initial portfolio, comprising an aggregate of 3,355 units as of December 31, 2025, are primarily independent living, with certain communities offering assisted living, memory care, and/or skilled nursing. These communities are often amenitized, apartment-like buildings with private residences ranging from studios to large apartments. We were formed in December 2025. Our principal executive office is located in Denver, CO.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.59 -0.03 (-1.85%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.